- Home
- PRK vs RARE Comparison
PRK vs RARE Comparison
Compare PRK & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRK
- RARE
- Stock Information
- Founded
- PRK 1908
- RARE 2010
- Country
- PRK United States
- RARE United States
- Employees
- PRK N/A
- RARE N/A
- Industry
- PRK Major Banks
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- PRK Finance
- RARE Health Care
- Exchange
- PRK Nasdaq
- RARE Nasdaq
- Market Cap
- PRK 2.8B
- RARE 2.6B
- IPO Year
- PRK N/A
- RARE 2014
- Fundamental
- Price
- PRK $172.37
- RARE $31.82
- Analyst Decision
- PRK Hold
- RARE Strong Buy
- Analyst Count
- PRK 2
- RARE 14
- Target Price
- PRK $170.00
- RARE $86.64
- AVG Volume (30 Days)
- PRK 46.5K
- RARE 1.3M
- Earning Date
- PRK 10-27-2025
- RARE 11-04-2025
- Dividend Yield
- PRK 2.47%
- RARE N/A
- EPS Growth
- PRK 22.52
- RARE N/A
- EPS
- PRK 10.28
- RARE N/A
- Revenue
- PRK $530,594,000.00
- RARE $610,159,000.00
- Revenue This Year
- PRK $9.63
- RARE $19.72
- Revenue Next Year
- PRK $2.66
- RARE $23.29
- P/E Ratio
- PRK $16.86
- RARE N/A
- Revenue Growth
- PRK 11.59
- RARE 26.77
- 52 Week Low
- PRK $137.97
- RARE $25.81
- 52 Week High
- PRK $207.99
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- PRK 56.83
- RARE 61.88
- Support Level
- PRK $169.14
- RARE $31.03
- Resistance Level
- PRK $175.54
- RARE $32.58
- Average True Range (ATR)
- PRK 3.07
- RARE 0.88
- MACD
- PRK 0.29
- RARE 0.38
- Stochastic Oscillator
- PRK 74.23
- RARE 79.62
About PRK Park National Corporation
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. Park National provides banking and other financial services to consumers and businesses.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.